Spherix Global Insights

August 11, 2017

Early US dermatologist’s views of Tremfya leave ground to be covered

From: The Pharma Letter

Early US dermatologist’s views of Tremfya leave ground to be covered

At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya’s (guselkumab) approval when aided. The drug was approved by the US Food and Drug Administration on July 13 as a treatment for moderate to severe plaque psoriasis…(read more)